Evidence map›Paper›PMID 42029189›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Infection of 5xFAD mice with a mouse-adapted SARS-CoV-2 does not alter Alzheimer's disease neuropathology yet induces widespread changes in gene expression across diverse cell types.

Susana Furman, Latifa Zayou, Kate Inman Tsourmas, Dominic Ibarra Javonillo, Gema M Olivarria, Yuting Cheng, Collin Pachow, Kellie Fernandez, Lucas Le, Robert A Edwards and 5 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Susana FurmanDepartment of Neurobiology and Behavior, University of California, Irvine, California, USA.
Latifa ZayouDepartment of Neurobiology and Behavior, University of California, Irvine, California, USA.
Kate Inman TsourmasDepartment of Neurobiology and Behavior, University of California, Irvine, California, USA.
Dominic Ibarra JavonilloDepartment of Neurobiology and Behavior, University of California, Irvine, California, USA.
Gema M OlivarriaDepartment of Neurobiology and Behavior, University of California, Irvine, California, USA.
Yuting ChengDepartment of Molecular Biology and Biochemistry, School of Biological Sciences, University of California, Irvine, California, USA.
Collin PachowDepartment of Molecular Biology and Biochemistry, School of Biological Sciences, University of California, Irvine, California, USA.
Kellie FernandezDepartment of Molecular Biology and Biochemistry, School of Biological Sciences, University of California, Irvine, California, USA.
Lucas LeDepartment of Neurobiology and Behavior, University of California, Irvine, California, USA.
Robert A EdwardsDepartment of Pathology & Laboratory Medicine, School of Medicine, University of California, Irvine, California, USA.
Dequina A NicholasDepartment of Molecular Biology and Biochemistry, School of Biological Sciences, University of California, Irvine, California, USA.
Gabriela Pacheco SanchezDepartment of Molecular Biology and Biochemistry, School of Biological Sciences, University of California, Irvine, California, USA.
Ralph S BaricDepartment of Epidemiology and Department of Microbiology &Immunology, School of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
Kim N GreenDepartment of Neurobiology and Behavior, University of California, Irvine, California, USA.
Thomas E LaneDepartment of Neurobiology and Behavior, University of California, Irvine, California, USA.ORCID 0000-0003-0392-0825

Funding

UC Irvine MODEL-ADU54AG054349 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Kim Green, FRANK M LAFERLA · 2017 to 2026
$71.9M
Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
Training in the Neurobiology of Aging and Alzheimers DiseaseT32AG000096 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI VIVEK SWARUP, Craig E Stark · 1985 to 2026
$9.6M
Mechanisms of MERS-CoV Entry, Cross-species Transmission and PathogenesisR01AI110700 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S, LI, FANG · 2015 to 2024
$7.4M
Defining mechanisms of disease and repair in a viral model of multiple sclerosisR35NS116835 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI Thomas E Lane · 2020 to 2026
$5.0M
Virus-host interactions: a multi-scale training programT32AI007319 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI SEMLER, BERT L, SHI, YONGSHENG · 1988 to 2024
$2.4M
Role of Disease-Associated Microglia in Alzheimer's diseaseR01AG081599 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Kim Green · 2024 to 2026
$2.3M
Impact of aging on human B cell vaccine responsesU01AI180164 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI Dequina Angelina Nicholas, Dorota Skowronska-Krawczyk · 2024 to 2026
$1.7M
Neuroimmunology Training Program at the University of California, IrvineT32NS121727 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI Kim Green, Thomas E Lane · 2022 to 2026
$854k
Elucidating the role of microglial Beta-hexosaminidase in microglial regulation of perineuronal nets in homeostasis and Alzheimer's diseaseF31NS141599 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI TSOURMAS, KATE INMAN · 2025 to 2025
$47k
Alzheimer's Association 105190National Institutes of Health (NIH-National Institute of Neurological Disorder and Stroke [NINDS]) R35NS116835NCI NIH HHS P30 CA062203NIAID NIH HHS R01 AI110700NIAID NIH HHS T32 AI007319NIAID NIH HHS U01 AI180164NIA NIH HHS R01 AG081599NIA NIH HHS T32 AG000096NIA NIH HHS U54 AG054349NIH-National Cancer Institute (NCI) 1F31NS141599NIH-National Cancer Institute (NCI) 5P30CA062203-26NIH-National Cancer Institute (NCI) 5T32 AI007319-33NIH-National Cancer Institute (NCI) U01AI180164NIH-National Institute on Aging (NIA) R01AG081599NIH-NIA Training T32 AG00096NINDS NIH HHS F31 NS141599NINDS NIH HHS R35 NS116835NINDS NIH HHS T32 NS121727
6 · The paper itself

Abstract

introductionThe COVID-19 pandemic underscored the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on worsening the severity of Alzheimer's disease (AD) neuropathology and disease progression.

methodsAged 5xFAD and wild-type (WT) mice were infected with a mouse-adapted SARS-CoV-2 (MA10), and extensive characterization of molecular and cellular changes within the brains was carried out.

resultsMA10 infection induced acute viral pneumonia. Viral RNA was undetectable within the brains of infected mice, and there was no evidence of glial activation or neuroinflammation. MA10 infection did not affect amyloid beta (Aβ) plaque volume or numbers in 5xFAD mice compared to uninfected mice. Spatial transcriptomics revealed altered expression of genes associated with homeostatic function in neurons, glia, and vascular endothelial cells. DISCUSSION: Collectively, these findings demonstrate that while MA10 infection did not affect AD neuropathology, there were numerous downstream effects on gene expression associated with resident central nervous system cell functions that may impact neurologic disease.

Indexed as

Alzheimer DiseaseBrainCOVID-19SARS-CoV-2Amyloid beta-PeptidesAnimalsDisease Models, AnimalGene ExpressionHumansMiceMice, TransgenicNeurogliaNeuronsPlaque, AmyloidSpatial TranscriptomicsAmyloid beta-PeptidesAlzheimer's disease neuropathologymouse‐adapted SARS‐CoV‐2neuroinflammationspatial transcriptomicsviral infection

Identifiers

PMID42029189
PMCPMC13108251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.